Company / Gross Profit per Share
UroGen Pharma Ltd. Gross Profit per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Profit per Share
$2.30
FY2025
5-year range
$1.03 / $2.45
FY2021-FY2025
Trend
+122.7%
vs FY2024
Sector context
#20 of 29
Health Care
What the data says
At $2.30, UroGen Pharma Ltd.'s gross profit per share ranks #20 of 29 in the Health Care sector. Gross Profit per Share has fluctuated over the past 10 years, ranging from $-0.05 in FY2018 to $7.59 in FY2016.
Based on SEC 10-K filings.
2.30 in FY2025 with a 5-year CAGR of +385.3%.
Declined from $2.45 to $2.30 over the past 2 years.
Health Care sector context is included.
Gross Profit per Share over time
Growth rates
- 3-Year CAGR
- +6.5%
- 5-Year CAGR
- +385.3%
- 10-Year CAGR
- -
Sector benchmark
#20 of 29 in Health CareTop 69% of 29This company $2.30 Sector average $8.10
▼
-71.6% below sector average
Key checks
Key Insights
- In FY2025, gross profit per share increased 122.7% year-over-year.
- Ranks #20 out of 29 companies in the Health Care sector.
- Peak gross profit per share was recorded in FY2016.
- Lowest gross profit per share in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.09 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross Profit per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.30 | +122.7% |
| FY2024 | $1.03 | -57.8% |
| FY2023 | $2.45 | +28.4% |
| FY2022 | $1.91 | -1.3% |
| FY2021 | $1.93 | +225880.5% |
| FY2020 | $0.00 | -99.8% |
| FY2019 | $0.47 | +1049.6% |
| FY2018 | -$0.05 | -106.3% |
| FY2017 | $0.78 | -89.8% |
| FY2016 | $7.59 | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026